It’s not often you get asked to play the role of the CEO of a small company making pricing and investment decisions for rare disease drugs, but attendees at the recent European Health Forum Gastein in Austria were given the chance to do just that in an entertaining simulation exercise run by Celgene vice-president Kevin Loth.
“Step into the shoes of a CEO of a pharmaceutical company and experience the complexity and trade-offs all stakeholders face when pricing